Conatus Pharmaceuticals Inc

Most Recent

  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”

    By Kenneth Smith
  • uploads///thermometer _
    Company & Industry Overviews

    Analysts’ Ratings for FibroGen and Its Peers in April 2018

    Of the seven analysts covering FibroGen in April, five have given the stock “strong buy” ratings, while two have given it “hold” ratings.

    By Kenneth Smith
  • uploads///NASH
    Company & Industry Overviews

    Which Gilead Sciences Portfolio Could Give a Long-Term Boost

    NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.